July 17, 2019
Published by pvreporter at July 17, 2019
Categories
Open Access Article – Petiti J, Rosso V, Lo Iacono M, et al. Curcumin induces apoptosis in JAK2‐mutated cells by the inhibition of JAK2/STAT and mTORC1 […]
June 10, 2019
Published by pvreporter at June 10, 2019
Slower walking pace linked to a higher likelihood of death and hospital visits; Researchers say gait speed should be used along with other vital signs to […]
March 27, 2019
Published by pvreporter at March 27, 2019
Categories
by Scott Sanders (guest author) A cancer diagnosis is devastating but it isn’t a death sentence (in most cases). Myeloproliferative Neoplasms, MPNs, are treatable and with […]
March 14, 2019
Published by pvreporter at March 14, 2019
Categories
Nationwide Population-based survey in Denmark Objective: We sought to determine the prevalence and severity of anxiety and depression among patients with Philadelphia-negative myeloproliferative neoplasms (MPNs) and […]
February 1, 2019
Dr. Verstovsek on Benefit of Ruxolitinib Treatment in PV Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at […]
December 21, 2018
by David Wallace MPN Cancer Connection is very pleased to announce a new partnership with the PAN Foundation. Myeloproliferative Neoplasm (MPN) patients may be eligible for […]
August 7, 2018
The largest ever study of its type is the first to definitively show an increased risk of blood cancers in relatives of patients. A team […]
July 16, 2018
Published by mpncancer at July 16, 2018
Categories
Brilliant work by Nathalie Cook lobbying the Australian Government for access to affordable drugs for Cancer Patients Inspiring, tenacious and rewarding work that will benefit the […]
April 9, 2018
Published by mpncancer at April 9, 2018
Categories
Publisher’s Note: My source at the American Society of Hematology (ASH) informed me that “initially MPNs aren’t going to be a primary focus, however, we expect […]
March 9, 2018
Metformin demonstrates antileukemic activity and may have clinical implications for the treatment of myeloproliferative neoplasms (MPN) in combination with ruxolitinib, according to a study published in Cell Death & […]
February 22, 2018
Published by mpncancer at February 22, 2018
Categories
AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE Researchers have discovered how some of the blood cancers known as myeloproliferative neoplasms (MPNs) evade the immune system. Their […]
February 1, 2018
Published by mpncancer at February 1, 2018
Categories
Imago BioSciences, a clinical-stage pharmaceutical company developing novel therapies for hematological and inflammatory diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted their […]
January 8, 2018
Published by mpncancer at January 8, 2018
Categories
Celgene Corporation (NASDAQ:CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for […]
December 27, 2017
The investigational Nutlin family antagonist idasanutlin demonstrated significant activity and was well tolerated after multiple cycles of exposure in patients with refractory polycythemia vera (PV). Data […]
December 1, 2017
Published by mpncancer at December 1, 2017
Categories
A Few Simple Criteria If your doc has never been to the ASH (American Society of Hematology) conference, the largest hematology convention in the world and […]
June 29, 2017
Published by mpncancer at June 29, 2017
Categories
This abstract is provided by Mads Emil Bjorn & Hans Carl Hasselbalch – Department of Hematology, Region Zealand, Roskilde, Denmark Abstract Introduction: The therapeutic landscape of […]
June 15, 2017
Published by mpncancer at June 15, 2017
Categories
UT (University of Texas) San Antonio makes Dr. Ruben Mesa head of their Cancer Center Dr Ruben Mesa, one of the leading MPN Specialist in the […]
June 5, 2017
Published by David Wallace at June 5, 2017
Categories
Abstract Myeloproliferative neoplasm cells recruit Gli1 positive mesenchymal stromal cells to transdifferentiate into fibrosis-causing myofibroblasts, a process that can be inhibited by a Gli inhibitor. Bone […]
April 28, 2017
Published by David Wallace at April 28, 2017
Understanding Polycythemia Vera (PV), A Rare Blood Cancer Behind the Mystery, Polycythemia Vera Every year, millions of patients, families and caregivers are impacted by cancer in […]
January 29, 2017
Published by mpncancer at January 29, 2017
Categories
A Solid Summary on the Latest MPN Research in 2017 Drs. Joseph R. Mikhael and Ruben A. Mesa analyze and discuss pertinent clinical studies and late […]
January 2, 2017
Published by mpncancer at January 2, 2017
Categories
Long Term Exposure to Radiation puts you at higher risk for MPN The Savannah River Site is on a list of qualified places for Special Exposure […]
December 21, 2016
A survey is being conducted to learn more about the most common symptoms experienced by ET patients, and how these symptoms affect the lives of patients. […]
October 18, 2016
Published by mpncancer at October 18, 2016
Categories
New Leukemia Research in Phase I/IIa Clinical Trial Biosight, an Israeli pharmaceutical development company that is working on a cure for leukemia, this week closed an […]
September 21, 2016
Published by mpncancer at September 21, 2016
Categories
“Researchers found that the mean hemoglobin and hematocrit levels of the polycythemia vera group were 16.7 g/dL and 50.4%, respectively, vs 13.4 g/dL and 40.3% in […]
September 20, 2016
Published by mpncancer at September 20, 2016
Categories
Key points The novel IFNα-2b AOP2014 administered once every two weeks (or once a month) has low toxicity and induces high and sustained response rates in […]
August 30, 2016
August 28, 2016
J Korean Med Sci. 2016 Oct;31(10):1579-1585. English. Published online Jul 22, 2016. http://dx.doi.org/10.3346/jkms.2016.31.10.1579 © 2016 The Korean Academy of Medical Sciences. Incidence, Survival and Prevalence Statistics of […]
August 17, 2016
Published by mpncancer at August 17, 2016
Categories
Scientists in China are about to become the first to use the game-changing gene-editing technology Crispr-Cas9 on humans. Last week, Nature reported that researchers at Sichuan […]
August 16, 2016
Published by mpncancer at August 16, 2016
Categories
Scientists have devised a way to destroy blood stem cells in mice without using chemotherapy or radiotherapy, both of which have toxic side effects. Blood stem […]
August 15, 2016
Conclusions: MPN patients are understudied and there are currently no studies that have explored the effects of physical activity on sympton burden and QoL in these […]
August 13, 2016
T cell Therapy shows promise fighting Blood Cancers Riddell’s preliminary findings on the success of T cell therapy to cure previously terminal cases of cancer made […]
August 5, 2016
This video is outstanding, well worth watching! Dr Silver and Dr Gisslinger in Europe have been using interferon successfully for 30 years. It would be my […]
April 1, 2016
Published by mpncancer at April 1, 2016
Categories
Learning about a cancer diagnosis can be an incredibly overwhelming experience, but it’s what you do afterwards that can make all the difference for the road […]